Home - Swiss Medtech Website

SWISS MEDTECH was established on 12 June 2017 following the merger of two national medtech organizations, FASMED and Medical Cluster. The new association represents the interests of the Swiss medtech industry. The aim is to maintain international competitiveness, innovative capacity, and to strengthen the domestic market.

Image source: BVMed

Whether it be syringes, implants, wheelchairs, or MRIs - medical technology supplies people, doctors, and hospitals with vital products and applications. The domestic medtech industry generates annual sales of 14.1 billion and exports of 10.6 billion Swiss francs. It contributes 2.2% of the GDP. Swiss Medtech supports the Swiss medtech industry's continuing contribution to health care and the economy, as well as its ability to remain competitive internationally.

The Association represents the interests of the industry and serves 1,350 companies and 54,500 employees. It is committed to rapid patient access to innovation and high-quality standards. Swiss Medtech also initiates specialised training programmes, challenges rising levels of regulation, and pushes for free trade and fair tariffs. Together with its specialist groups and partners, the Association is committed to favourable conditions and to an attractive setting for research and other professional activities within Switzerland.

30.4.18– The Swiss Medtech Association and its partner Innosuisse are hosting the largest medtech event in Switzerland for the first time - and are expecting over 600 participants. In addition to specialist lectures, breakout sessions and a Science Slam, the main attraction will be the presentation of the Swiss Medtech Awards.

Prepare yourself in time for the consequences of Brexit12.4.18– 30% to 40% of EU medical device market authorisations have received CE marks in the UK. These products may no longer be recognized following Brexit and the MDR transition period. Recertifications could also be delayed. A checklist compiled by Medtech Europe helps affected companies prepare for these scenarios.

28.3.18– For many medtech companies, the time period granted for the necessary adaptations until 2020 will probably be insufficient, and certain products may become unavailable. At the MDR/IVDR conference of Swiss Medtech and the SVDI representatives of industry and authorities will discuss possible solutions and cooperation models.

16.3.18– Starting 30 March 2019, British "Notified Bodies" and representatives could lose their legal status and would no longer be authorised to issue EU Certifications. Swiss Medtech recommends that all affected companies follow the negotiations closely.

8.3.18– The EPO received nearly 166 000 European patent applications in 2017. Switzerland again topped the ranking. And Medical technology remains the field with the greatest number of patent applications (up +6.2%).

6.3.18– “Adjustments, in particular to the Therapeutic Products Act (TPA) and to the Human Research Act (HRA), aim to build a solid statutory basis for a complete overhaul of the MedDO. The complete revision of it is scheduled to enter into force in the first half of 2020,” the government said.